Abstract
The aim of this open-label pilot study was to assess the efficacy and safety of the novel anticonvulsant agent, levetiracetam, for the treatment of alcohol dependence. A maximal dose of 2000 mg was administered daily for 10 weeks to alcohol dependent subjects (n = 20). Mean reported ethanol intake declined significantly from 5.3 to 1.7 standard drinks per day. Levetiracetam was well tolerated by most subjects.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alcoholism / drug therapy*
-
Alcoholism / prevention & control
-
Anticonvulsants / pharmacology
-
Anticonvulsants / therapeutic use*
-
Brain / drug effects
-
Female
-
Humans
-
Levetiracetam
-
Male
-
Middle Aged
-
Piracetam / analogs & derivatives*
-
Piracetam / pharmacology
-
Piracetam / therapeutic use
-
Receptors, AMPA / drug effects
-
Receptors, GABA-A / drug effects
-
Receptors, Glycine / drug effects
Substances
-
Anticonvulsants
-
Receptors, AMPA
-
Receptors, GABA-A
-
Receptors, Glycine
-
Levetiracetam
-
Piracetam